Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)

• Company Description    Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California. Number of Employees: 286

• Price / Volume Information    Yesterday's Closing Price: $9.04 Daily Weekly Monthly 20 Day Moving Average: 756,266 shares Shares Outstanding: 76.45 (millions) Market Capitalization: $691.10 (millions) Beta: 2.10 52 Week High: $29.56 52 Week Low: $8.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.39% -15.90% 12 Week -22.20% -29.33% Year To Date -52.02% -56.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1700 OWENS STREET SUITE 205 - SAN FRANCISCO,CA 94158 USA ph: 415-660-5320 fax: - ir@nurixtx.com http://www.nurixtx.com

• General Corporate Information    Officers Arthur T. Sands - Chief Executive Officer; President and Director Julia P. Gregory - Chairman Hans van Houte - Chief Financial Officer Anil Kapur - Director Lori A. Kunkel - Director Peer Information Nurix Therapeutics, Inc. (CORR.) Nurix Therapeutics, Inc. (RSPI) Nurix Therapeutics, Inc. (CGXP) Nurix Therapeutics, Inc. (BGEN) Nurix Therapeutics, Inc. (GTBP) Nurix Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67080M103 SIC: 2834 Fiscal Year Fiscal Year End: November Last Reported Quarter: 05/01/25 Next Expected EPS Date: 10/10/25 Share - Related Items Shares Outstanding: 76.45 Most Recent Split Date: (:1) Beta: 2.10 Market Capitalization: $691.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.91 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/10/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: 7.82 EPS Growth vs. Year Ago Period: 26.76% vs. Previous Quarter: 22.39% Sales Growth vs. Year Ago Period: 264.34% vs. Previous Quarter: 138.75% ROE 08/31/25 - - 05/31/25 - -45.26 02/28/25 - -47.49 ROA 08/31/25 - - 05/31/25 - -34.71 02/28/25 - -36.10 Current Ratio 08/31/25 - - 05/31/25 - 6.82 02/28/25 - 6.26 Quick Ratio 08/31/25 - - 05/31/25 - 6.82 02/28/25 - 6.26 Operating Margin 08/31/25 - - 05/31/25 - -234.57 02/28/25 - -369.40 Net Margin 08/31/25 - - 05/31/25 - -234.57 02/28/25 - -369.40 Pre-Tax Margin 08/31/25 - - 05/31/25 - -233.61 02/28/25 - -369.08 Book Value 08/31/25 - - 05/31/25 - 5.87 02/28/25 - 6.31 Inventory Turnover 08/31/25 - - 05/31/25 - - 02/28/25 - - Debt-to-Equity 08/31/25 - - 05/31/25 - 0.00 02/28/25 - 0.00 Debt-to-Capital 08/31/25 - - 05/31/25 - 0.00 02/28/25 - 0.00

Powered by Zacks Investment Research ©